Sold as Portrazza. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Necitumumab (sold as Portrazza), first approved Nov 24, 2015, with 0 new uses approved and 0 published complete response letters.
| Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerMetastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma · Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 | Active, not recruiting | Feb 26, 2020 |
| Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Non-Small Cell Lung Cancer · AstraZeneca | Phase 2 | Active, not recruiting | May 10, 2019 |
| Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma · National Cancer Institute (NCI) | Phase 1 | Active, not recruiting | Jul 14, 2015 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 24, 2015 | PortrazzaBLA 125547 · New molecular entity | Eli Lilly Co | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA